IL286353A - Combinations of iadademstat for cancer therapy - Google Patents

Combinations of iadademstat for cancer therapy

Info

Publication number
IL286353A
IL286353A IL286353A IL28635321A IL286353A IL 286353 A IL286353 A IL 286353A IL 286353 A IL286353 A IL 286353A IL 28635321 A IL28635321 A IL 28635321A IL 286353 A IL286353 A IL 286353A
Authority
IL
Israel
Prior art keywords
iademastat
combinations
cancer treatment
cancer
treatment
Prior art date
Application number
IL286353A
Other languages
English (en)
Hebrew (he)
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of IL286353A publication Critical patent/IL286353A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL286353A 2019-03-25 2021-09-13 Combinations of iadademstat for cancer therapy IL286353A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382206 2019-03-25
PCT/EP2020/058362 WO2020193631A1 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Publications (1)

Publication Number Publication Date
IL286353A true IL286353A (en) 2021-10-31

Family

ID=66175363

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286353A IL286353A (en) 2019-03-25 2021-09-13 Combinations of iadademstat for cancer therapy

Country Status (13)

Country Link
US (1) US20220175698A1 (cg-RX-API-DMAC10.html)
EP (1) EP3946295B1 (cg-RX-API-DMAC10.html)
JP (2) JP7824627B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210142614A (cg-RX-API-DMAC10.html)
CN (2) CN113573702A (cg-RX-API-DMAC10.html)
AU (1) AU2020249493B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021016171A2 (cg-RX-API-DMAC10.html)
CA (1) CA3132473A1 (cg-RX-API-DMAC10.html)
IL (1) IL286353A (cg-RX-API-DMAC10.html)
MX (1) MX2021011610A (cg-RX-API-DMAC10.html)
PH (1) PH12021552326A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109025XA (cg-RX-API-DMAC10.html)
WO (1) WO2020193631A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US20190256929A1 (en) * 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy

Also Published As

Publication number Publication date
CN113573702A (zh) 2021-10-29
JP7824627B2 (ja) 2026-03-05
SG11202109025XA (en) 2021-09-29
JP2026077769A (ja) 2026-05-13
KR20210142614A (ko) 2021-11-25
AU2020249493A1 (en) 2021-09-16
PH12021552326A1 (en) 2022-06-27
JP2022526525A (ja) 2022-05-25
EP3946295A1 (en) 2022-02-09
BR112021016171A2 (pt) 2021-10-05
CA3132473A1 (en) 2020-10-01
CN121422229A (zh) 2026-01-30
US20220175698A1 (en) 2022-06-09
WO2020193631A1 (en) 2020-10-01
EP3946295B1 (en) 2026-08-05
AU2020249493B2 (en) 2025-08-28
MX2021011610A (es) 2021-10-13

Similar Documents

Publication Publication Date Title
IL282663A (en) Bt1718 for use in treating cancer
IL284199A (en) Csf1r inhibitors for use in treating cancer
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
IL284875A (en) Lasofoxifene treatment of breast cancer
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL282093A (en) Combination therapy for cancer
DK3768830T5 (da) Cancerterapi
GB201903546D0 (en) Cancer treatment
IL291170A (en) Treatment of hr deficient cancer
IL281845A (en) Combination therapy for the treatment of cancer
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
IL281600A (en) Methods of treating cancer
DK3576740T3 (da) Cancerbehandling
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
IL308399A (en) Methods of treating cancer
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
IL264589A (en) Combination therapy for the treatment of pancreatic cancer
PT3952858T (pt) Método de tratamento de tumores
IL272379A (en) Methods of treating cancer by inhibiting setd2
IL287652A (en) Cancer treatment
IL285466A (en) Cancer treatment
EP4025203A4 (en) CANCER TREATMENT
SG11202010528XA (en) Combinations for treating cancer
IL281281A (en) Combination therapy for the treatment of prostate cancer